Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28703015
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
#MMPMID28703015
Remington G
; Addington D
; Honer W
; Ismail Z
; Raedler T
; Teehan M
Can J Psychiatry
2017[Sep]; 62
(9
): 604-616
PMID28703015
show ga
OBJECTIVE: The present guidelines address the pharmacotherapy of schizophrenia in
adults across different stages, phases, and symptom domains. METHOD: Guidelines
were developed using the ADAPTE process, which takes advantage of existing
guidelines. Six guidelines were identified for adaptation, with recommendations
extracted from each. For those specific to the pharmacotherapy of schizophrenia
in adults, a working group selected between guidelines and recommendations to
create an adapted guideline. RESULTS: Recommendations can be categorized into 6
areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3)
relapse prevention and maintenance treatment, 4) treatment-resistant
schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom
domains. For each category, recommendations are made based on the available
evidence, which is discussed and linked to other established guidelines.
CONCLUSIONS: In most cases, evidence-based recommendations are made that can be
used to guide current clinical treatment and decision making. Notably, however,
there is a paucity of established evidence to guide treatment decision making in
the case of clozapine-resistant schizophrenia, a subsample that represents a
sizable proportion of those with schizophrenia.
free
free
free
